Opinion|Videos|October 21, 2024
Future Outlook for Atopic Dermatitis Treatments
Key Takeaways
- Novel oral systemic agents are being developed, targeting specific pathways in atopic dermatitis pathophysiology for improved efficacy and safety.
- Personalized medicine approaches and biomarkers are expected to enhance treatment outcomes by tailoring therapies to individual patient profiles.
Medical experts share their final thoughts on the future of atopic dermatitis treatment with oral systemic agents.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Please share final thoughts on the future of atopic dermatitis treatment with oral systemic agents.
Advertisement
Related to this article
In this Q&A, Armand explains why eczema visits spike during wildfire smoke events and how allergic patients can protect themselves.
In this feature, several leaders in the dermatology space were asked how far we have come and where the field is headed in precision medicine.
New research links wildfire smoke to lasting respiratory decline and skin flares, months after exposure ends.
George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
Advertisement
Advertisement
Trending on HCPLive
1
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
2
FAQ: What the Expanded Marstacimab Approval Means for Hemophilia A, B
3
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
4
Q&A: Zasocitinib Response in the Scalp, Nails, Palms and Soles
5